Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25792568.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3180.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Smoothened inhibitors represent the first class of targeted drugs approved for use in advanced and metastatic basal cell carcinoma. For many patients with limited treatment options, this drug class has led to significant clinical improvements, but is not without side effects. In this review, we outline the basic mechanism of smoothened inhibitors and the most commonly observed cutaneous and extracutaneous side effects. We also highlight possible mechanisms for these adverse events and current management strategies.
Medical subject headings
- Antineoplastic Agents
- Basal Cell Carcinoma
- Drug-Related Side Effects and Adverse Reactions
- Receptors, G-Protein-Coupled